RU2711371C2 - Аденовирус, содержащий альбумин-связывающий участок - Google Patents

Аденовирус, содержащий альбумин-связывающий участок Download PDF

Info

Publication number
RU2711371C2
RU2711371C2 RU2016146664A RU2016146664A RU2711371C2 RU 2711371 C2 RU2711371 C2 RU 2711371C2 RU 2016146664 A RU2016146664 A RU 2016146664A RU 2016146664 A RU2016146664 A RU 2016146664A RU 2711371 C2 RU2711371 C2 RU 2711371C2
Authority
RU
Russia
Prior art keywords
adenovirus
protein
genome
albumin
genes
Prior art date
Application number
RU2016146664A
Other languages
English (en)
Russian (ru)
Other versions
RU2016146664A (ru
RU2016146664A3 (he
Inventor
БОНАСТРЕ Рамон АЛЕМАНИ
ЭКСПОСИТО Луис Альфонсо РОХАС
Original Assignee
Фундасио Институт Д`Инвестигасио Биомедика Де Бельвитхе (Идибелл)
Институт Катальа Д`Онколохия (Ико)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фундасио Институт Д`Инвестигасио Биомедика Де Бельвитхе (Идибелл), Институт Катальа Д`Онколохия (Ико) filed Critical Фундасио Институт Д`Инвестигасио Биомедика Де Бельвитхе (Идибелл)
Publication of RU2016146664A publication Critical patent/RU2016146664A/ru
Publication of RU2016146664A3 publication Critical patent/RU2016146664A3/ru
Application granted granted Critical
Publication of RU2711371C2 publication Critical patent/RU2711371C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016146664A 2014-04-30 2015-04-30 Аденовирус, содержащий альбумин-связывающий участок RU2711371C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382162.7A EP2940128A1 (en) 2014-04-30 2014-04-30 Adenovirus comprising an albumin-binding moiety
EP14382162.7 2014-04-30
PCT/EP2015/059593 WO2015166082A1 (en) 2014-04-30 2015-04-30 Adenovirus comprising an albumin-binding moiety

Publications (3)

Publication Number Publication Date
RU2016146664A RU2016146664A (ru) 2018-05-30
RU2016146664A3 RU2016146664A3 (he) 2018-06-28
RU2711371C2 true RU2711371C2 (ru) 2020-01-16

Family

ID=50774820

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016146664A RU2711371C2 (ru) 2014-04-30 2015-04-30 Аденовирус, содержащий альбумин-связывающий участок

Country Status (12)

Country Link
US (3) US10604549B2 (he)
EP (2) EP2940128A1 (he)
JP (1) JP6639412B2 (he)
KR (1) KR102628234B1 (he)
CN (1) CN106471125B (he)
AU (1) AU2015254535B2 (he)
BR (1) BR112016025297B1 (he)
CA (1) CA2946650C (he)
IL (1) IL248590B (he)
MX (1) MX2016014187A (he)
RU (1) RU2711371C2 (he)
WO (1) WO2015166082A1 (he)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
EP3665202A1 (en) 2017-08-09 2020-06-17 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
WO2019074842A1 (en) * 2017-10-09 2019-04-18 Keith Black ONCOLYTIC ANTICANCER IMMUNOTHERAPIES AND METHODS OF USE
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP2022502074A (ja) * 2018-09-10 2022-01-11 ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド 改変された腫瘍溶解性ウイルス、組成物、およびその使用
EP3906038A4 (en) * 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
CA3138527C (en) 2019-04-29 2024-03-12 Mayo Foundation For Medical Education And Research Multivalent pd-l1 binding compounds for treating cancer
AU2020325825A1 (en) 2019-08-05 2022-03-17 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
EP4148126A1 (en) * 2020-03-25 2023-03-15 Curigin Co.,Ltd. Immunoevasive anti-tumor adenovirus
US20230293590A1 (en) 2020-08-10 2023-09-21 Mesoblast International Sárl Cellular compositions and methods of treatment
CN116271066A (zh) * 2021-12-13 2023-06-23 康希诺生物股份公司 一种重组腺病毒载体疫苗吸入给药递送系统
CN114159556B (zh) * 2021-12-14 2023-06-16 中国人民解放军军事科学院军事医学研究院 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体
WO2023120762A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
WO2023121177A1 (ko) * 2021-12-21 2023-06-29 (주)큐리진 면역 회피성 항종양 아데노바이러스
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
CN115624524B (zh) * 2022-10-25 2023-10-27 中国医科大学附属第一医院 Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112929A1 (en) * 2005-05-31 2008-05-15 Imre Kovesdi Shielded adenoviral vectors and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3377363D1 (en) 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
WO2001045746A2 (en) * 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7445929B2 (en) 2000-05-26 2008-11-04 Dainippon Sumitomo Pharma Co., Ltd. Recombinant adenovirus vector having a reduced side effect
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
DE602007004470D1 (de) 2006-04-28 2010-03-11 Univ Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
CN101781636A (zh) 2009-01-19 2010-07-21 中国人民解放军第二军医大学东方肝胆外科医院 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
US20130058897A1 (en) 2010-04-14 2013-03-07 Mogam Biotechnology Research Institute Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080112929A1 (en) * 2005-05-31 2008-05-15 Imre Kovesdi Shielded adenoviral vectors and methods of use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEDLEY S.J. et all., "Assesment of Genetic Shielding for Adenovirus Vectors", The open Gene Theerapy Journal, vol.2, 2009, pp.1-11. ТЕРНОВОЙ В.А. и др., *
HONGJU WU et all., "Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation", Journal of virology, vol.79, no.6, 01.03.2005, pp.3382-3390. *
HONGJU WU et all., "Identification of Sites in Adenovirus Hexon for Foreign Peptide Incorporation", Journal of virology, vol.79, no.6, 01.03.2005, pp.3382-3390. HEDLEY S.J. et all., "Assesment of Genetic Shielding for Adenovirus Vectors", The open Gene Theerapy Journal, vol.2, 2009, pp.1-11. ТЕРНОВОЙ В.А. и др., "Конструирование перспективных онколитических рекомбинантных аденовирусов, экспрессирующих ген белка алоптина", Вестник Томского государственного университета, 2013, 3(23), стр.100-110. СВЯТЧЕНКО В.А. и др., "Онколитические аденовирусы в терапии злокачественных новообразований: современное состояние и перспективы", Молекулярная биология, 2012, том. 46,4, стр. 556-569. *
СВЯТЧЕНКО В.А. и др., "Онколитические аденовирусы в терапии злокачественных новообразований: современное состояние и перспективы", Молекулярная биология, 2012, том. 46,4, стр. 556-569. *
ТЕРНОВОЙ В.А. и др., "Конструирование перспективных онколитических рекомбинантных аденовирусов, экспрессирующих ген белка алоптина", Вестник Томского государственного университета, 2013, 3(23), стр.100-110. *

Also Published As

Publication number Publication date
US10604549B2 (en) 2020-03-31
MX2016014187A (es) 2017-05-03
RU2016146664A (ru) 2018-05-30
BR112016025297B1 (pt) 2022-08-30
IL248590B (he) 2021-01-31
BR112016025297A2 (pt) 2017-10-17
KR102628234B1 (ko) 2024-01-22
US11578104B2 (en) 2023-02-14
RU2016146664A3 (he) 2018-06-28
AU2015254535B2 (en) 2020-08-13
CN106471125B (zh) 2021-04-06
JP6639412B2 (ja) 2020-02-05
KR20160145825A (ko) 2016-12-20
CA2946650A1 (en) 2015-11-05
US20170051022A1 (en) 2017-02-23
AU2015254535A1 (en) 2016-12-01
JP2017514483A (ja) 2017-06-08
US20200181208A1 (en) 2020-06-11
EP3137599A1 (en) 2017-03-08
IL248590A0 (he) 2016-12-29
US20230331786A1 (en) 2023-10-19
CA2946650C (en) 2023-07-11
EP2940128A1 (en) 2015-11-04
WO2015166082A1 (en) 2015-11-05
CN106471125A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
RU2711371C2 (ru) Аденовирус, содержащий альбумин-связывающий участок
JP5075839B2 (ja) 癌の処置のための腫瘍崩壊性アデノウイルス
JP2012525833A (ja) 癌治療のための腫瘍溶解アデノウイルス
JP2014224141A (ja) アデノウイルスおよびそれをコードしている核酸の新たな使用
KR102167934B1 (ko) 재조합 아데노바이러스 및 이를 포함하는 줄기세포
EP1196616B1 (en) Replication-competent anti-cancer vectors
EP2391722B1 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
EP4148126A1 (en) Immunoevasive anti-tumor adenovirus
Goradel et al. Strategies for enhancing intratumoral spread of oncolytic adenoviruses
WO2020166727A1 (ja) ヒト３５型アデノウイルスを基板とした腫瘍溶解性ウイルス
Saini et al. Importance of viruses and cells in cancer gene therapy
TW202102677A (zh) 經修飾腺病毒及含有其之醫藥
Kangasniemi Improving oncolytic adenoviral therapies for gastrointestinal cancers and tumor initiating cells
Särkioja Adenoviral gene therapy for non-small cell lung cancer